Andere Sprachen Precision BioSciences, Inc.

Aktien

A400AS

US74019P2074

DTIL

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:01:56 19.04.2024			% 5 Tage	% 1. Jan.
10.16 ^USD	-5.22%		-27.90%	-7.03%

16.04.	Transcript : Precision BioSciences, Inc. - Special Call
16.04.	Precision BioSciences, Inc. gibt die Rückgabe von Programmen und den Abschluss der Zusammenarbeit mit Prevail Therapeutics bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	16.04.
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16.04.
Precision BioSciences, Inc. Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	16.04.
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Precision BioSciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.03.
Precision BioSciences: Q4 Earnings Snapshot	27.03.
Earnings Flash (DTIL) PRECISION BIOSCIENCES Posts Q4 Revenue $7M	27.03.
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update	27.03.
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024	20.03.
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy	19.03.
IECURE SECURES APPROVAL FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY TO EXPAND THE OTC-HOPE STUDY OF ECUR-506	07.03.
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06.03.
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	06.03.
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	04.03.
Precision BioSciences Launches $40 Million Public Offering; Shares Slump	01.03.
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	01.03.
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants	29.02.
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20.02.
Precision BioSciences, Inc. Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	20.02.
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness	14.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Precision BioSciences, Inc.

Aktien

A400AS

US74019P2074

DTIL

Andere Sprachen

Filter